Robert Clifford to Immunogenicity, Vaccine
This is a "connection" page, showing publications Robert Clifford has written about Immunogenicity, Vaccine.
Connection Strength
1.880
-
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Hum Vaccin Immunother. 2019; 15(4):786-799.
Score: 0.644
-
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15?months: A phase III, randomized, non-inferiority trial. Vaccine. 2018 Sep 11; 36(38):5781-5788.
Score: 0.621
-
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial. Lancet Infect Dis. 2024 Jul; 24(7):687-697.
Score: 0.229
-
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. N Engl J Med. 2022 Nov 03; 387(18):1673-1687.
Score: 0.208
-
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2020 08; 39(8):763-770.
Score: 0.178